Back to Search Start Over

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Authors :
Pungolino, Ester
D'adda, Mariella
Perego, Alessandra
Orlandi, Ester Maria
Turrini, Mauro
Borin, Lorenza Maria
Iurlo, Alessandra
Artale, Salvatore
Latargia, Maria Luisa
Anghilieri, Michela
Malato, Simona
Trojani, Alessandra
Spina, Francesco
Maria Cristina, Carraro
Pioltelli, Maria Luisa
Elena, Chiara
Bucelli, Cristina
Spedini, Pierangelo
Rossi, Giuseppe
Morra, Enrica
Cairoli, Roberto
Source :
Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p2889-2889, 1p
Publication Year :
2017

Abstract

BackgroundChronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder, hallmarked by the BCR-ABL fusion gene which encodes for a constitutively activated BCR/ABL tyrosine-kinase, effectively treated with Tyrosine-Kinase Inhibitors (TKIs). The first line TKI Imatinib (IM) can obtain a high cumulative CCyR; compared to IM, deeper and faster molecular responses can be obtained in newly diagnosed CML patients with the second generation TKIs, Nilotinib (NIL) and Dasatinib. Despite the three TKIs have been evaluable as first line therapy for a long time, our experience largely concern the second generation TKIs after IM but not evidence are reported regarding IM after second generation TKIs.

Details

Language :
English
ISSN :
00064971 and 15280020
Volume :
130
Issue :
1, Number 1 Supplement 1
Database :
Supplemental Index
Journal :
Blood
Publication Type :
Periodical
Accession number :
ejs56856441
Full Text :
https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889